INNOVA recently unveiled the NIDEK RS-1 Glauvas OCT, marking a major milestone in our diagnostic portfolio. This cutting-edge OCT device combines unprecedented speed, precision, and advanced analytics, positioning it as a game-changer in ocular diagnostics. With a scan rate of 250,000 A-scans per second — three times faster than its predecessor — the RS-1 Glauvas provides rapid, high-resolution imaging that addresses patient fixation issues, offering enhanced clarity and comfort during exams. The system’s deep imaging capability extends to 4.2 mm, perfect for capturing details in the optic nerve and vascular arcade, critical for diagnosing and managing glaucoma and retinal conditions.

Our Canadian launch strategy ensured that all key components were meticulously covered. We equipped our reps with comprehensive training, marketing materials, and competitive insights to emphasize the RS-1’s unique features. All internal stakeholders — Clinical Support, Service, and Order Management —  were pivotal to the successful launch.

The launch took place in Toronto and Montreal where our teams engaged in a training program that included pre-reading, quizzes, and hands-on demonstrations in competitive sales scenarios. This comprehensive approach not only prepared the team to communicate the RS-1’s capabilities confidently but also strengthened our commitment to clinical excellence and customer satisfaction.

INNOVA is proud to lead with the RS-1 Glauvas, setting a new standard for OCT technology in Canada. With this launch, we’re not just introducing a product; we’re enhancing the tools Canadian eye care professionals need to elevate patient care.